The resting cell: a chemotherapeutic problem. Part II.
D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D002477:Cells / Q000378:metabolism; D003260:Contact Inhibition; D000242:Cyclic AMP / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D005110:Extracellular Space; D005796:Genes; D006131:Growth Inhibitors / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D007111:Immunity, Cellular; D037102:Lectins / Q000494:pharmacology; D008934:Mitogens / Q000627:therapeutic use; D008938:Mitosis / Q000187:drug effects / Q000528:radiation effects; D011830:Radiation Effects; D013268:Stimulation, Chemical; D014118:Toxins, Biological / Q000494:pharmacology
D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D006133:Growth Substances; D006728:Hormones; D037102:Lectins; D008934:Mitogens; D014118:Toxins, Biological; D004247:DNA; D000242:Cyclic AMP